Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Prostate Cancer
Interventions: Decipher, Prolaris, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score); Device · Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 8
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 4 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib, Magnetic Resonance Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma
Interventions: Ensartinib, ALKATI by Customized Nanostring Assay; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Middletown, New Jersey • Montvale, New Jersey • East White Plains, New York + 1 more

Conditions: Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Hepatocellular Cancer
Interventions: National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Neoplasm, Lung Neoplasm, Sarcoma, Breast Neoplasm
Interventions: rh IL-12, rh IL-2; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
Interventions: OPB-101; Biological
Lead sponsor: Outpace Bio, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Detroit, Michigan • Minneapolis, Minnesota • Buffalo, New York + 1 more

Conditions: Lung Cancer, NSCLC, NSCLC Adenocarcinoma
Interventions: Not listed
Lead sponsor: Myriad Genetic Laboratories, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Dental Pulp Disease
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 16 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: Archival tissue specimen and immunohistochemistry staining; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Miami, Florida • Florence, South Carolina

Conditions: Milk Expression, Breast
Interventions: Bupivacaine liposome; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hepatitis B
Interventions: Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes, Metabolic Syndrome x
Interventions: borage/echium oil combination, fish oil, corn oil; Drug · Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Glioblastoma
Interventions: 18F-FluorThanatrace; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 22 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Wounds and Injuries
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cystic Fibrosis
Interventions: digitoxin, placebo; Drug · Other
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cystic Fibrosis, Pulmonary Exacerbation
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Prematurity; Extreme, Feeding Disorder Neonatal, Breast Milk Expression, Growth Failure, Microbial Colonization
Interventions: Protein-enriched human milk diet, Usual human milk diet; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 4 Days
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neoplasms
Interventions: FdCyd + THU; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 6
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 3 more

Conditions: COPD
Interventions: Roflumilast Placebo, Roflumilast; Drug
Lead sponsor: University of Miami; Other
Eligibility: 45 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: Microarray analysis, Laboratory biomarker analysis; Genetic · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: High Risk for Developing Breast Cancer
Interventions: Nonlinear Aerobic Training, Height, Weight, BMI measure, Blood draw, Cardiopulmonary exercise test; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)

Sodium Channel Expression in Human Teeth

A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Exparel PK and Breast Milk Excretion

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects

18F-FluorThanatrace (PET/CT) in Glioblastoma

Gene Expression Profiles in Healing and Non-Healing Wounds

Phase II Study of Digitoxin to Treat Cystic Fibrosis

Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies

Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients

Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer

Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk

FdCyd and THU for Advanced Solid Tumors

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD

Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer